HAS @HAS_sante cite notre étude en référence : "A ce jour, la preuve d’efficacité de l’hydroxychloroquine +/- azithromycine dans le traitement de la COVID-19 n’est pas établie dans des études de phase III contrôlées, randomisées."
pages 5-6 has-sante.fr/jcms/p_3186049…
"Aucune recommandation internationale ou nationale ne préconise son utilisation en dehors d’un encadrement dans un essai clinique"
Cité également dans un rapport du département de la Sécurité intérieure, US Homeland Security, Science & Technology 🇺🇸
dhs.gov/publication/st…
Le ministère américain écrit "Hydroxychloroquine does not benefit mild-moderate COVID-19 cases, was associated with adverse cardiac events in severely ill patients, and increases mortality when combined with azithromycin"
Several large clinical trials have stopped
administering hydroxychloroquine due to lack of efficacy. Other existing studies have found no benefit of
hydroxychloroquine (with or without azithromycin) as well as cardiac side effects and elevated risk of mortality.
Hydroxychloroquine does not protect individuals from infection either before or after exposure. The FDA revoked its EUA for the drug on 6/15/20
=> L'HCQ ne marche pas du tout à ce jour
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.